Aim. To evaluate the prevalence and the influence on survival of depressive symptoms in a European cohort of endstage renal disease (ESRD) patients on renal replacement therapy (RRT). Methods. In a prospective fashion, symptoms of depression were evaluated in ESRD patients on RRT using the depression subscore of the Hospital Anxiety and Depression Scale (HADS). Fatal and non-fatal clinical events were determined during a 1-year follow-up. Results. Of 101 patients with ESRD, 42% showed manifest depressive symptoms, defined as a HADS-D score ≥7. No association was found between depressive symptoms and severity of somatic disease. During follow-up, all-cause mortality was significantly higher in patients with depressive symptoms above threshold (n = 42, mortality: 26%) compared to patients with depressive symptoms below threshold (n = 59, mortality 8%), (crude HR 3.3, CI 1.2-9.6, P = 0.02). The excess in mortality was mainly caused by a higher incidence of septicaemia (0 versus 12%, P = 0.01). After adjustment for clinical parameters, this association between depressive symptoms and mortality became even stronger. There was no significant difference observed in the incidence of cardiovascular events. Conclusions. Patients with ESRD treated with dialysis show a high level of depressive symptoms that is independently associated with poor survival. Future research should address appropriate therapeutic regimens.
Introduction
Chronic diseases are frequently associated with depression. However, in chronically ill patients, it can be difficult to diagnose a depressive disorder, as it shares common physical symptoms with somatic illness. It is known that depressive symptoms frequently occur in patients with end-stage renal disease (ESRD) who are treated with dialysis [1] [2] [3] . Former studies conducted in US patients with ESRD found prevalence rates of depressive disorder up to 34%; however, the current prevalence in European cohorts is unknown [4] .
Recent studies suggest a relationship between depressive symptoms, diminished quality of life and prognosis [5] . Different screening tools and definitions for depressive symptoms have been used. Screening tools included self-reported depression [1] , the Zung Depression Rating scale [2] and the Beck Depression Inventory [4] . Applying such diverse screening methods, decreased survival rates were observed in patients scoring high on these instruments [1, 2, 4] . However, as depressive disorder and ESRD can have similar physical symptoms, there is a need for a practical, clinical applicable screening tool that does not focus on the shared symptomatology. For this purpose, the Hospital Anxiety and Depression Scale (HADS) was chosen in the current study. The HADS is specifically designed for use in somatically ill populations and therefore does not contain somatic items [6] .
In the European population of patients with ESRD on haemodialysis (HD) or peritoneal dialysis (PD), the relationship between depressive symptoms and survival had yet to be investigated. Using a single-centred, prospective cohort design, this specific relationship was explored.
Methods

Study design
The study was a prospective, single-centre registry assessing the association of depressive symptoms on survival in a patient cohort with ESRD on HD and PD treatments.
Patients
All prevalent ESRD patients in the Sint Lucas Andreas Hospital aged 18 years or more who received treatment with HD or PD were eligible for the study. The recruitment period ran over a 12-month period from February 2006 until January 2007. Patients who did not speak Dutch sufficiently to be able to complete the HADS questionnaire and patients with cognitive or perceptual disorders that prevented them from completing the 232 R. K. Riezebos et al.
questionnaires without help were excluded from the study. In addition, patients who were too severely ill to complete the questionnaire were excluded. Informed consent was obtained from all patients prior to enrolment. The study was approved by the local medical ethical committee.
Assessment
Psychiatric assessment. The depression subscore of the HADS was used to quantify depressive symptoms. The HADS was chosen as a screening tool to provide a simple, fast and clinical useful self-rating scale for screening purposes.
The HADS consists of seven items on symptoms of depression and seven on anxiety, both with a duration of 1 week. The HADS has been validated as a depression screening instrument for ESRD patients. For the chosen cut-off value, the sensitivity and specificity of the HADS-D subscale were 81% and 80.5%, respectively [7] .
All patients completed the Dutch translation of the HADS. The HADS-D scores the severity of symptoms of depression (7 items scored 0-21) and was measured at baseline. Higher scores on this scale correspond to worse depressive symptoms. Based on the current literature, a dichotome cut-off for significant depressive symptoms, a HADS-D value of 7, was chosen [8] .
Demographic and psychiatric characteristics. Patient variables were identified from medical records: age, gender, marital and employment status. In addition, psychiatric history and present prescription of antidepressants were noted.
Clinical characteristics. At baseline, several clinical characteristics were recorded including DM, cardiovascular disease [congestive heart failure, previous myocardial infarction (MI) and known coronary artery disease] and cause of ESRD. Details of dialysis treatment such as time on dialysis and dialysis modality were noted. In addition, several biochemical parameters were measured: serum albumin (mmol/L), serum haemoglobin (mmol/L) and renal parameters such as Kt/V (weekly) and residual renal function (mL/min).
Data management. Data, including the results of the HADS questionnaire, were obtained by an independent health care worker. The treating physicians were not aware of the results until the follow-up period of the study was completed.
Intention to treat. All included patients were treated according to the intention to treat principle. While the questionnaire used in this study was not validated for this patient population, yet, a high score was insufficient to diagnose clinical significant depression. The patients were treated by local standards and not routinely evaluated by a psychiatrist.
Follow-up
At 1-year follow-up after patient enrolment, clinical data were collected. Discharge summaries were reviewed for accuracy as to the cause of death or hospitalization.
Endpoints
Primary endpoint of the study was 1-year all-cause mortality. Secondary endpoints were cardiovascular mortality, the occurrence and number of hospital admissions and the occurrence of cardiovascular events such as cardiac arrest, MI, new-onset heart failure, stroke and need for urgent coronary revascularization. In addition, the occurrence of dialysis-related complications was noted as well as the weight gain or loss in 1 years' time.
Statistical analyses
Descriptive statistics and patient data listings were used to summarize the data collected on the CRF. Continuous variables were summarized using means and standard deviations or medians with inter-quartile ranges when appropriate. Categorical variables were described using frequencies and percentages.
Continuous variables were compared with the use of Student's t-test or the Mann-Whitney U-test for skewed data. Comparison between groups for categorical variables was performed using the chi-square or Fisher exact test when appropriate. A survival analysis was performed using Kaplan-Meier models. In addition, regression analysis was performed using time-dependent Cox proportional hazard models. A P-value of <0.05 (two sided) was used to indicate statistical significance.
Results
Patients
One hundred and fifty-three prevalent dialysis patients were screened, of which 101 patients (81 HD and 20 PD) enrolled into the study (Figure 1 ). Of the 52 patients excluded, 29 patients were not eligible due to language difficulties, 3 because of perceptual and 1 because of cognitive deficits. Additionally, 2 patients were physically too ill to complete the questionnaires and 17 patients refused participation. Apart from age (participants 63.6 ± 13.6 years versus nonparticipant 55.1 ± 16.0 years, P = 0.003), there were no differences in baseline characteristics between participants and non-participants.
The baseline characteristics of the included patients are shown in Table 1 . Comparison between HD and PD patients demonstrated no differences except for serum albumin concentration. Therefore, in the analysis, the cohort was treated as a homogenous group.
Depressive symptoms were highly prevalent in patients with ESRD. Forty-two patients (41.6%) had depressive symptoms, defined as a HADS-D score ≥7. No significant differences in demographical data were found between patients with or without depressive symptoms (Table 2) . Only one patient with depressive symptoms received antidepressant medication at the time of inclusion. This means only 2.4% of all patients with depressive symptoms, as measured with the HADS-D questionnaire, were treated with an antidepressant. Due to the observational nature of the study, no patient received additional psychiatric evaluation during the follow-up period other than on request of the physician in charge of the patient as part of the overall routine treatment.
The only observed difference between patients with and without depressive symptoms was the number of different types of medication used (7.07 ± 2.53 versus 8.31 ± 3.10, P < 0.05) ( Table 2) . 
Endpoint analysis
The patients with depressive symptoms, as estimated by a HADS-D subscore of >7, showed an increased mortality rate as compared to patients without depressive symptoms. After a 1-year follow-up period, the incidence of death in the non-depressed patients was 8% and in the depressed patients 26%, P = 0.02 (Table 3) . At 1 year, the unadjusted hazard ratio (HR) for mortality was 3.3 and confidence interval (CI) 1.2-9.6. As shown in the Kaplan-Meier curves, the divergence between the mortality rates in the depressed and non-depressed patients started after a 3-month followup (Figure 2) .
The difference in mortality between both groups was merely driven by an excess of infection-related deaths (Table 3 ). Although the number of patients in the study were limited, this difference proved significant (0 versus 12%, P = 0.01). Noteworthy is that the number of cardiovascularrelated deaths was similar (7%) in both groups. In the patient group with low HADS-D scores, one patient withdrew from dialysis, while in the group with high HADS-D scores, three patients died after withdrawal from dialysis. This difference was not significant, probably due to the limited number of patients. The decision to withdraw was in all occasions shared by patient, family and medical staff. More details on the cause of death per patient are provided in the online supplement A. The occurrence of other clinical events such as sudden cardiac death, MI, urgent coronary revascularization, stroke and new congestive heart failure was similar in both groups. In addition, no difference was observed in the number of (22) 12 (20) 10 ( hospital admissions between both groups ( Table 3) . As there were no relevant differences found between depressed and non-depressed patients (Table 2) , clinically important variables were included in a multivariate analysis. In different models, the relationship between depressive symptoms and mortality was adjusted for various demographical, clinical and treatment variables. After adjustment, the predictive value of depressive symptoms for mortality increased even more (Table 4) .
Discussion
This prospective cohort of Dutch ESRD patients treated with renal replacement therapy (RRT) showed a high prevalence of depressive symptoms. Although the depressed and non-depressed group had similar somatic characteristics, the patients with depressive symptoms demonstrated a marked increase in mortality.
Recently, Hedayati et al. documented similar results in the US cohort of haemodialysis patients [9] . In this group, a 26.5% incidence of clinical depression and a strong association between depression and hospitalizations or death were found. However, these results were mainly determined by a high rate of hospitalization in the depressed group. A clear influence on mortality, as was found in the current study, was not observed.
Despite the empirical evidence that depression increases the risk of, mainly cardiovascular, morbidity and mortality, there is no commonly accepted model that describes the underlying mechanisms [10] [11] [12] . The current study showed no relationship linking depressive symptoms to major adverse cardiac events. The increase in mortality in patients with depressive symptoms was mainly due to a high incidence of infection-related deaths. This suggests a relationship between depression and immunologic dysfunction. Indeed, the relationship between psychological stress and inflammatory disease has long been acknowledged [13] . Multiple studies demonstrated diminished cellular and neurohumoral immune responses in the presence of a depression [14, 15] . However, whereas previous studies showed an apparent altered immune response in depressed patients, a significant increase in sepsis-related deaths has-to our knowledge-never been reported before.
Both direct and indirect pathways could play a role in understanding the relationships between depression and immunity. Depression is associated with autonomic imbalance and the activation of the hypothalamic-pituitary-adrenal (HPA) axis [16] . There is growing evidence of cytokines interrupting the negative feedback mechanism of the HPA axis by cortisol, leading to a continuing increase in immune activation [17] [18] [19] . This leads to immune dysfunction, coagulation abnormalities, platelet and vascular endothelial dysfunction [20] [21] [22] [23] [24] [25] [26] . Immunological dysfunction is important, as the major part of mortality in dialysis patients is linked to inflammation-induced atherosclerosis and infection. Although direct inflammation markers were not assessed in the current study, albumin, as negative acute phase protein, showed similar concentrations in the depressed and non-depressed subjects.
Chronic immune activation, platelet and coagulation abnormalities and concurrent cardiovascular disease are often seen in patients with ESRD treated with RRT. This in itself poses a risk for the development of depressive symptoms, as communication between the brain and immune system seems to be reciprocal [23, 24] .
Indirect pathways refer to psychosocial and behavioural mediators related with depression. Depression is associated with poor health behaviour, maladaptive coping style, social isolation and chronic life stress [27] . Behavioural factors such as smoking, alcohol and drug abuse, low physical activity, a poor diet and failure to adhere to medical recommendations, such as hygiene and fluid restrictions, mediate the relationship of depressive disorders with poor survival [28] [29] [30] . The observed infection-related deaths, such as PD peritonitis, may partly be contributed to the lack of personal hygiene. In addition, the current study showed a trend in higher interdialytic weight gain in the HD group, which could be regarded as a diminished compliance with fluid restriction (Table 3) .
Finally, it could be postulated that severity of somatic disease leads to an increase in depressive symptoms. In this scenario, depression is merely a symptom of severe somatic dysregulation and hence indirectly associated with poor survival. This scenario is unlikely, as after adjustment for a series of clinical parameters the association of depressive symptoms with mortality became even stronger.
Depressive symptoms are highly prevalent in ESRD patients treated with dialysis and are associated with poor survival. The high prevalence of depressive symptoms may not only result from the high impact of RRT on the somatic well-being, but also from the psychological and social burden which it poses on the individual. This probably results in a vicious circle in which all factors can contribute synergistically towards a clinical deterioration on many fronts, ultimately resulting in death. The depressed population currently studied most likely suffered from immunological dysfunction.
Strikingly, in the current cohort, treatment for clinical depression was scarce. The exclusively observational nature of the study prevented confounding of the results by applying intercurrent psychiatric treatment. Only when clinically suspected by the physician in charge were patients referred for psychiatric evaluation. This finding emphasizes the difficulty to recognize depression in daily practice in this specific population. Although as yet there is no definite proof that treatment of depression in chronically ill patients improves survival, it will have a major impact on improving quality of life. Therefore, clinicians in charge of chronically ill patients should routinely screen their patients for depressive symptoms. Structured evaluation of depressive symptoms would increase the identification of patients with a significant depression and, hence, provide the foundation for effective psychiatric treatment. The HADS questionnaire is a simple and effective first screening tool for the identification of the population at a risk for depression. Further psychiatric evaluation then verifies those patients with a clinical depression requiring (pharmacological) therapy.
Future studies are needed to evaluate the possible pathophysiologic pathways and the impact of psychiatric interventions on morbidity and mortality in these high-risk patients.
Limitations
Although the HADS is known to be a valid and clinical useful screening tool for depressive symptoms, a limitation of the study is the lack of use of the DSM IV-based gold standard for diagnosing depression.
Conclusions
Patients with ESRD treated with dialysis show a high level of depressive symptoms which is independently associated with poor survival. The impact of depression on ESRD patients is evident and should not be ignored. Appropriate therapeutic regimens and trials are needed.
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Supplementary data are available online at http://ndt.oxfordjournals.org.
